Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

被引：6

作者：

Usmani, Saad Z. ^{[1
]}

Nahi, Hareth ^{[2
]}

Mateos, Maria-Victoria ^{[3
]}

Lokhorst, Henk M. ^{[4
]}

Chari, Ajai ^{[5
]}

Kaufman, Jonathan L. ^{[6
]}

Moreau, Philippe ^{[7
]}

Oriol, Albert ^{[8
]}

Plesner, Torben ^{[9
,10
,11
]}

Benboubker, Lotfi ^{[12
]}

Hellemans, Peter ^{[13
]}

Masterson, Tara ^{[14
]}

Clemens, Pamela L. ^{[15
]}

Ahmadi, Tahamtan ^{[15
]}

Liu, Kevin ^{[16
]}

San-Miguel, Jesus ^{[17
]}

机构：

[1] Levine Canc Inst Carolinas HealthCare Syst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA

[2] Karolinska Univ Hosp, Karolinska Inst, Div Hematol, Huddinge, Sweden

[3] Univ Hosp Salamanca IBSAL, Salamanca, Spain

[4] Vrije Univ Amsterdam Med Ctr, Dept Hematol, Amsterdam, Netherlands

[5] Tisch Canc Inst, Mt Sinai Sch Med, New York, NY USA

[6] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[7] Nantes Univ Hosp, Dept Hematol, Nantes, France

[8] HGTiP, Inst Catala Oncol, Barcelona, Spain

[9] Univ So Denmark, Vejle Hosp, Ctr Little Belt, Dept Hematol, Vejle, Denmark

[10] Vejle Hosp, Dept Hematol, Vejle, Denmark

[11] Univ So Denmark, Vejle, Denmark

[12] CHU Tours Hop Bretonneau, Tours, France

[13] Janssen Res & Dev, Beerse, Belgium

[14] Janssen Res & Dev, Spring House, PA USA

[15] Janssen Res & Dev, LLC, Spring House, PA USA

[16] Janssen Res & Dev, LLC, Raritan, NJ USA

[17] Clin Univ Navarra CIMA, IDISNA, Pamplona, Spain

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.1149.1149

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1149

引用

页数：6

共 50 条

[11] Corticosteriod tapering in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) receiving subcutaneous daratumumab (DARA SC): Part 3 of the open-label, multicenter, phase Ib PAVO Study.
Nahi, Hareth
Usmani, Saad Zafar
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Yang, Shiyi
Hellemans, Peter
Tromp, Brenda J.
Luo, Man
Zemlickis, Donna
Farnsworth, Andrew
Chari, Ajai
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[12] OPROZOMIB (OPZ) AND DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED RESULTS FROM DOSE ESCALATION IN A PHASE 1B/2, MULTICENTER, OPEN-LABEL STUDY
Hari, P.
Shain, K. H.
Voorhees, P.
Gabrail, N.
Abidi, M.
Zonder, J.
Boccia, R.
Richardson, P. G.
Neuman, L.
Wong, H.
Dixon, S.
Prada, C. P.
HAEMATOLOGICA, 2015, 100 : 254 - 255
[13] Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study
Hari, Parameswaran N.
Shain, Kenneth H.
Voorhees, Peter M.
Gabrail, Nashat
Abidi, Muneer H.
Zonder, Jeffrey
Boccia, Ralph V.
Richardson, Paul G.
Neuman, Linda L.
Dixon, Sandra J.
Prada, Claudia Paba
BLOOD, 2014, 124 (21)
[14] An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma
Moreau, Philippe
Mateos, Maria-Victoria
Blade, Joan
Benboubker, Lotfi
de la Rubia, Javier
Facon, Thierry
Comenzo, Raymond L.
Fay, Joseph W.
Qin, Xiang
Masterson, Tara
Schecter, Jordan
Ahmadi, Tahamtan
San Miguel, Jesus
BLOOD, 2014, 124 (21)
[15] Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study
Lonial, Sagar
San-Miguel, Jesus F.
Martinez-Lopez, Joaquin
Mateos, Maria-Victoria
Blade, Joan
Benboubker, Lotfi
Oriol, Albert
Arnulf, Bertrand
Chari, Ajai
Pineiro, Luis
Wu, Kaida
Wang, Jianping
Doshi, Parul
Schecter, Jordan
Moreau, Philippe
BLOOD, 2017, 130
[16] Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma
Chari, Ajai
Lonial, Sagar
Suvannasankha, Attaya
Fay, Joseph W.
Arnulf, Bertrand
Ifthikharuddin, Jainulabdeen J.
Qin, Xiang
Masterson, Tara
Nottage, Kerri
Schecter, Jordan M.
Ahmadi, Tahamtan
Weiss, Brendan
Krishnan, Amrita
Lentzsch, Suzanne
BLOOD, 2015, 126 (23)
[17] A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and/or Refractory Multiple Myeloma
Walling, Jackie M.
Matusow, Bernice
Nichols, Christine
Singh, Parmveer
Inokuchi, Kerry
Bollag, Gideon
BLOOD, 2024, 144 : 7022 - 7023
[18] A phase 1, open-label, dose-escalation study of pralatrexate incombination with bortezomib in patients with relapsed/refractory multiple myeloma
Dunn, Tamara J.
Dinner, Shira
Price, Elizabeth
Coutre, Steven E.
Gotlib, Jason
Hao, Ying
Berube, Caroline
Medeiros, Bruno C.
Liedtke, Michaela
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (02) : 253 - 259
[19] Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: PALOMA, an open-label, multicenter, dose escalation phase 1b study.
Krebs, Matthew
Johnson, Melissa Lynne
Cho, Byoung Chul
Park, Keunchil
Haddish-Berhane, Nahor
Zemlickis, Donna
Mitselos, Anna
Meacle, Francis
Knoblauch, Roland Elmar
Hellemans, Peter
Minchom, Anna Rachel
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[20] Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma
Chari, Ajai
Hari, Parameswaran
Bahlis, Nizar J.
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Dholaria, Bhagirathbhai
Garfall, Alfred L.
Goldschmidt, Hartmut
Kortuem, K. Martin
Krishnan, Amrita Y.
Martin, Thomas
Morillo Gilles, Daniel
Oriol, Albert
Reece, Donna E.
Rodriguez, Cesar
Rodriguez-Otero, Paula
San-Miguel, Jesus F.
Usmani, Saad Z.
Verona, Raluca I.
Lin, Shun Xin Wang
Prior, Thomas J.
Wade, Mark
Weiss, Brendan M.
Goldberg, Jenna D.
Askari, Elham
BLOOD, 2021, 138

← 1 2 3 4 5 →